Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued U.S. patent. Whereas previous issued patents in the Aclarion portfolio limit the use of propionic acid (PA) identification by magnetic resonance spectroscopy (MRS) to the disc, this new patent expands Aclarion’s ability to use MRS to identify PA throughout the body to identify potential sources of infection and pain.
“While propionic acid is a normal human physiological metabolite, there are many known side effects and disorders associated with propionic acid,” said Jeff Lotz, PhD, Vice Chair Research, University of California at San Francisco.
MRS is an existing capability of leading magnetic resonance imaging (MRI) scanners which are commonly used today for medical imaging. MRI creates images of the soft tissue structures of the body while MRS generates spectral data information on the levels of various chemical biomarkers within the soft tissues such as proteins, carbohydrates, acids, etc. However, conventional MRS post-processing approaches can be challenging and fall short of generating sufficient quality data for reliable chemical analysis. Several of Aclarion’s patents relate to novel inventions that address many of these challenges, resulting in more reliable, higher quality spectral data for more sophisticated chemical biomarker analysis, ensuring the accuracy and reliability of the Nociscan solution and other MRS applications.
ACON shares took on nine cents, or 1.9%, to $4.76.
